Table 1

Baseline characteristics

Adalimumab (n=94)Infliximab (n=120)Etanercept (n=16)Total group (n=230)
*p<0.05.
Age (years), mean (SD)55.2 (12.3)56.4 (12.6)50.6 (12.2)55.5 (12.4)
Female, No (%)59 (63)86 (72)10 (63)155 (67)
Weight (kg), mean (SD)71.2 (12.5)74.5 (13.6)70.6 (9.6)72.7 (12.8)
Disease duration (years), mean (SD)11.4 (8.32)11.9 (8.9)10.1 (10.5)11.6 (8.7)
RF positivity, No (%)87 (93)98 (82)14 (88)199 (87)
Previous DMARD use, mean (SD)4.5 (1.8)4.1 (1.6)3.3 (1.7)4.2 (1.8)
Patients receiving prednisone, No (%)48 (51)*29 (24)3 (19)80 (35)
DAS28 at start, mean (SD)6.4 (1.1)*5.9 (1.1)5.8 (1.5)6.1 (1.1)